: Trades at ~10.3x to 14.5x 2026 adjusted earnings.
: 3.2% to 3.5% (annualized ~70p expected for 2026). Market Cap : ~£110 Billion. 📈 Investment Thesis: Why Buy? buy gsk shares
: Specialty medicines (HIV, Oncology, Respiratory) now drive over 40% of revenue. : Trades at ~10
: Five major product approvals were achieved in 2025; two more expected in 2026 for bepirovirsen and tebipenem . 📈 Investment Thesis: Why Buy
: Strong market position with Shingrix (shingles) and Arexvy (RSV).
: Settled ~93% (80,000 cases) of U.S. Zantac litigation for $2.2 billion, removing a major long-term overhang. ⚠️ Risks to Consider Stock Story: GSK - The Merchants Trust
Investing in (LSE: GSK ) in April 2026 presents a transition from a historically "unloved" stock to a growth-oriented specialty biopharma player. Since demerging its consumer health arm (Haleon) in 2022, GSK has significantly outpaced the FTSE 100. GSK plc (GSK) GBX 1,831.50 9.86% since Jan 2, 2026 As of Apr 27, 19:52 GMT+3 • Disclaimer Apr 27, 2026 Open2,018.00 Mkt cap$109.86B USD 52-wk high2,282.00 High2,023.00 P/E ratio14.49 52-wk low1,288.60 Low1,999.00 Div yield3.28% Financial Snapshot (April 2026) Market Price : ~2,012 GBX (up nearly 60% in 12 months).